Solara Active Pharma Sciences experienced a significant turnaround in its financial performance for the fourth quarter of FY26, with its stock price rising 15.20% to ₹584.85 following the announcement of a consolidated net profit of ₹9.60 crore, contrasting sharply with a loss of ₹2.10 crore in Q4 FY25. Revenue from operations soared by 41.86%, reaching ₹387.29 crore, largely fueled by a 36% increase in the base business and a remarkable 61% rise in the Ibuprofen segment, which generated ₹849 crore. Despite these gains, the company reported a full-year consolidated net loss of ₹7.41 crore for FY26, compared to a profit of ₹0.54 crore in FY25. EBITDA rose 21% to ₹61.7 crore, although the EBITDA margin declined to 15.8% from 18.3% year-over-year. CEO Sandeep Rao noted the company's strategic shift towards sustainable growth, while acknowledging ongoing challenges in the Ibuprofen business, which operates at a negative 21% EBITDA margin. To address these challenges, the company has engaged bankers to explore strategic options for the Ibuprofen segment.